GW2580 是口服有效的,选择性的c-Fms激酶抑制剂,体外实验中在 0.06 μM 时可完全抑制人 cFMS 激酶。GW2580 是 ATP 与 cFMS 激酶结合的竞争性抑制剂,并且可以抑制集落刺激因子 1 信号传导。
生物活性 | GW2580 is an orally bioavailable and selective inhibitor ofc-Fmskinasewhich completely inhibits human cFMS kinasein vitroat 0.06 μM. GW2580 acts as a competitive inhibitor of ATP binding to the cFMS kinase and inhibits colony-stimulating-factor-1 signaling[1]. |
IC50& Target | |
体外研究 (In Vitro) | GW2580 completely inhibits the growth of CSF-1-dependent mouse myeloid M-NFS-60 cells at 0.7 μM. GW2580 at 0.8-1 μM completely blocks the ability of CSF-1 to induce the growth of mouse M-NFS60 myeloid cells and human monocytes[1]. GW2580 causes a 30-40% inhibition of PTH-induced calcium release at 0.1-0.3 μM, with higher concentrations of 1, 3, and 10 μM completely inhibiting the PTH response[1]. GW2580 inhibits CSF1R phosphorylation in RAW264.7 murine macrophages stimulated with 10 ng/mL with IC50of approximately 10 nM[2]. GW2580 also inhibits TRKA activity with IC50of 0.88 μM[3].
|
体内研究 (In Vivo) | GW2580 (Oral administration; 20 and 80 mg/kg) produces a dose-related decrease in the number of tumor cells, with the 80 mg/kg dose completely blocking tumor growth[1]. GW2580 (Oral administration; 20 and 80 mg/kg) has gave maximal plasma concentrations of 1.4 and 5.6 μM, respectively[1]. GW2580 (50 mg/kg; twice a day from days 0 to 21, 7 to 21, or 14 to 21) inhibits joint connective tissue and bone destruction in a 21-day adjuvant arthritis model[3].
Animal Model: | Female C3H/HEN mice or female CD-1 nude mice weighing 22-26 g[1] | Dosage: | 20 and 80 mg/kg | Administration: | Oral administration | Result: | Produced a dose-related decrease in the number of tumor cells, with the 80 mg/kg dose completely blocking tumor growth. |
Animal Model: | Female C3H/HEN mice or female CD-1 nude mice weighing 22-26 g[1] | Dosage: | 20 and 80 mg/kg (Pharmacokinetic Study) | Administration: | Oral administration | Result: | Had gave maximal plasma concentrations of 1.4 and 5.6 μM, respectively. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : 33.33 mg/mL(90.96 mM;Need ultrasonic) Ethanol :< 1 mg/mL(insoluble) 配制储备液 1 mM | 2.7292 mL | 13.6459 mL | 27.2918 mL | 5 mM | 0.5458 mL | 2.7292 mL | 5.4584 mL | 10 mM | 0.2729 mL | 1.3646 mL | 2.7292 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.08 mg/mL (5.68 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (5.68 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.08 mg/mL (5.68 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (5.68 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.08 mg/mL (5.68 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (5.68 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|